neurodegenerative diseases/tyrosine

Throughout this application various patent and nonpatent publications are referenced, full citations of which are provided. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to

FIELD OF THE INVENTION This invention is in the field of the neurotrophic receptors and their ligands. More specifically this invention relates to the receptor-like tyrosine kinase Bsk and its corresponding ligand and to therapeutic and diagnostic applications which employ the Bsk receptor or

BACKGROUND Neurodegenerative diseases include genetic and sporadic disorders associated with progressive nervous system dysfunction. It has been estimated that one of four Americans will develop a neurodegenerative condition in their lifetimes. Generally, however, the underlying mechanisms causing

BACKGROUND Neurodegenerative diseases include genetic and sporadic disorders associated with progressive nervous system dysfunction. It has been estimated that one of four Americans will develop a neurodegenerative condition in their lifetimes. Generally, however, the underlying mechanisms causing

FIELD OF THE INVENTION This invention relates to the field of protein tyrosine phosphatase inhibition. BACKGROUND OF THE INVENTION This invention relates to a novel class of phosphonic acid derivatives that are inhibitors of PTP-1B. Reversible protein tyrosine phosphorylation, coordinated by the

FIELD OF THE INVENTION This invention relates to the field of protein tyrosine phosphatase inhibition. BACKGROUND OF THE INVENTION This invention relates to a novel class of phosphonic acid derivatives that are inhibitors of PTP-1B. Reversible protein tyrosine phosphorylation, coordinated by the

The present invention relates to the field of medical approaches for ocular diseases that may lead to partial or total blindness. The invention provides useful tools to be applied topically into the eyes, including peptides and analogs of these peptides. BACKGROUND ART Retinal neurodegenerative

FIELD OF THE INVENTION The present invention relates to a complex comprising the neurotrophic factors: nerve growth factor (NGF) and trk-proto-oncogene receptor protein. The present invention also relates to methods for detecting the presence of NGF ligand, and trk-proto-oncogene receptor

FIELD OF THE INVENTION The present invention relates to a complex comprising the neurotrophic factors: nerve growth factor (NGF) and trk-proto-oncogene receptor protein. The present invention also relates to methods for detecting the presence of NGF ligand, and trk-proto-oncogene receptor

FIELD OF THE INVENTION The invention described herein relates to methods of preventing or treating disorders in patients suffering from the effects of neuronal degeneration. The invention is based in part on the discovery that activation of the c-ret receptor is necessary for neuronal cell

The present invention relates to a vector system. In particular, the present invention relates to a lentiviral vector system for the treatment of Parkinson's disease. BACKGROUND Parkinson's Disease Parkinson's disease (PD) is a neurodegenerative disorder characterized by the loss of the

BACKGROUND OF THE INVENTION 1. Field of the Invention The invention relates to substituted carboxylic acids and more specifically to such compounds that are useful in the treatment of diabetes. More specifically, it relates to such compounds that are capable of inhibiting Protein tyrosine

The present invention relates to novel compounds that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety

The present invention relates to novel compounds that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety

The present invention relates to novel compounds that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety